A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next
Issued on behalf of Conexeu Sciences Inc. As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (NASDAQ:CNXU) is aiming its investigational CXU™ platform squarely at it RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- Energy Metal News News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into mainstream weight loss so quickly that roughly 1 in 8 U.S. adults have now used one. And as those millions of people reshape their bodies, they a
